This study developed bispecific T-cell engager (BiTE)-albumin fusion proteins with tunable FcRn affinity to extend serum half-life and enhance anti-tumor efficacy. Using a double-humanized HSA/hFcRn mouse model, the researchers demonstrated that optimizing albumin-FcRn binding affinity modulates BiTE pharmacokinetics and improves therapeutic outcomes in vivo.
Tuning FcRn binding affinity in BiTE-albumin fusions allows programmable half-life extension, improving therapeutic window and anti-tumor responses.
Humanized double Knockin mouse model expressing human serum albumin (HSA) and human neonatal Fc receptor (hFcRn), developed by genOway (AlbuMus).
Immuno-oncology, Bispecific antibodies, FcRn-targeted therapy, T cell redirection
Humanized Knockin model, HSA Knockin, hFcRn Knockin, Albumin–FcRn interaction studies
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
